Medtronic (NYSE:MDT) has won FDA approval for a deep brain stimulation system for Parkinson’s disease.The approval is for BrainSense Adaptive deep brain stimulation (DBS)and BrainSense Electrode ...

Now Medtronic has enhanced its Percept™ DBS neurostimulators with exclusive BrainSense™ Adaptive technology, introducing aDBS for people living with Parkinson's. This feature personalizes ...

Medtronic received Food and Drug Administration approval for the BrainSense Adaptive deep brain stimulation (DBS) device for people with Parkinson’s disease, a movement disorder of the nervous ...

Now Medtronic has enhanced its Percept™ DBS neurostimulators with exclusive BrainSense™ Adaptive technology†, introducing aDBS for people living with Parkinson's. This feature personalizes ...

Deep brain stimulation (DBS) has been instrumental in managing Parkinson's symptoms for over three decades. Medtronic's Percept™ DBS neurostimulators now incorporate BrainSense™ Adaptive ...

Now Medtronic has enhanced its Percept DBS neurostimulators with exclusive BrainSense Adaptive technology †, introducing aDBS for people living with Parkinson's. This feature personalizes ...

Medtronic's BrainSense aDBS personalizes Parkinson's therapy in real-time, minimizing manual adjustments for better symptom control. BrainSense Electrode Identifier speeds up initial DBS ...

New closed-loop system self-adjusts DBS therapy to individual brain activity in real time; the largest commercial launch of brain-computer interface technology ever GALWAY, Ireland, Feb. 24, 2025 ...

GALWAY, Ireland - Medtronic plc (NYSE:MDT), a prominent player in the Healthcare Equipment & Supplies industry with a market capitalization of $115.42 billion, has announced the FDA approval of its ...